SCHEMBL672185

SCHEMBL672185

Oc1[c]nccn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7106917 0.65
SCHEMBL4933630 0.65
SCHEMBL448317 0.65
SCHEMBL558752 0.65
SCHEMBL451629 0.65
SCHEMBL17474307 0.65
SCHEMBL450465 0.65
SCHEMBL9170 0.65
SCHEMBL3278665 0.64
SCHEMBL4931800 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423357-B1 UREA DERIVATIVES WITH ANTIPROTEOLYTIC ACTIVITY SANOFI AVENTIS DEUTSCHLAND (DE) 2006-09-06 EP claimed
EP-1423357-A2 UREA DERIVATIVES WITH ANTIPROTEOLYTIC ACTIVITY Aventis Pharma Deutschland GmbH (DE) 2004-06-02 EP claimed
US-6706715-B2 REVERSIBLE INHIBITORS OF THE BLOOD CLOTTING ENZYME FACTOR VIIA AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-03-16 US claimed
US-6646010-B2 Enzyme inhibitors such as N(3-benzyloxycarbonylamino-2-hydroxy -4-phenylbutyl)-N-isoamylamine, used for prophylaxis of viral diseases and infections; lymphadenopathy associated virus G. D. SEARLE & CO. 2003-11-11 US claimed
US-20030199527-A1 Use of corticotropin releasing factor antagonists and related compositions HAMANAKA ERNEST S (US) 2003-10-23 US claimed
US-20030176439-A1 Urea derivatives with antiproteolytic activity AVENTIS PHARMA DUTSCHLAND GMBH 2003-09-18 US claimed
EP-1293213-A1 PREVENTIVES/REMEDIES FOR POSTOPERATIVE STRESS JAPAN TOBACCO INC. (JP) 2003-03-19 EP claimed
WO-2003002524-A2 UREA DERIVATIVES WITH ANTIPROTEOLYTIC ACTIVITY AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-01-09 WO claimed
EP-0691128-B1 Use of CRF antagonists PFIZER (US) 2002-12-11 EP claimed
US-6403599-B1 STROKE, HYPERTENSION, TACHYCARDIA, AND CONGESTIVE HEART FAILURE, OSTEOPOROSIS, PREMATURE BIRTH, PSYCHOSOCIAL DWARFISM, STRESS-INDUCED FEVER, ULCER, DIARRHEA, POST-OPERATIVE ILEUS, AND COLONIC HYPERSENSITIVITY, CARDIOVASCULAR DISORDERS PFIZER INC 2002-06-11 US claimed
EP-0773023-A1 New uses for corticotropin releasing factor (CRF) antagonists PFIZER INC. (US) 1997-05-14 EP claimed
EP-0764153-A1 SUBSTITUTED PYRAZOLES HAVING CORTICOTROPIN-RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY PFIZER INC. (US) 1997-03-26 EP claimed
EP-0691128-A1 Methods of administering CRF antagonists PFIZER INC. (US) 1996-01-10 EP claimed
WO-1995033727-A1 SUBSTITUTED PYRAZOLES HAVING CORTICOTROPIN-RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY PFIZER INC. (US) 1995-12-14 WO claimed
EP-0674642-A1 PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS PFIZER INC. (US) 1995-10-04 EP claimed
EP-0674625-A1 AMINO-SUBSTITUTED PYRAZOLES HAVING CRF ANTAGONISTIC ACTIVITY PFIZER INC. (US) 1995-10-04 EP claimed
EP-0674624-A1 PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONIST ACTIVITY PFIZER INC. (US) 1995-10-04 EP claimed
WO-1994013643-A1 PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONIST ACTIVITY PFIZER INC. (US) 1994-06-23 WO claimed
WO-1994013644-A1 AMINO-SUBSTITUTED PYRAZOLES HAVING CRF ANTAGONISTIC ACTIVITY PFIZER INC. (US) 1994-06-23 WO claimed
WO-1994013677-A1 PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS PFIZER INC. (US) 1994-06-23 WO claimed